{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:11025495",
      "entity_text" : "cholesterol",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0490" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "All three treatments significantly reduced HbA 1c compared with baseline (-0.3% [colesevelam], -0.6% [rosiglitazone], and -0.4% [sitagliptin]; P < 0.05 for all); however, colesevelam significantly reduced LDL cholesterol levels as well (-11.6%; P = 0.0012), suggesting colesevelam may be an ideal second-line treatment option providing significant glucose- and lipid lowering benefits in patients with type 2 diabetes.",
  "reading_complete" : "2020-07-28T15:35:26Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:33:01Z",
  "trigger" : "levels",
  "evidence" : [ "cholesterol levels" ],
  "pmc_id" : "3632187",
  "score" : 0
}